Taito Esaki
A5055212193- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer therapeutics and mechanisms
- Fibroblast Growth Factor Research
- Esophageal Cancer Research and Treatment
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Advanced Breast Cancer Therapies
- Radiomics and Machine Learning in Medical Imaging
- PI3K/AKT/mTOR signaling in cancer
- Sarcoma Diagnosis and Treatment
- Cancer Research and Treatments
- Frailty in Older Adults
- Multiple and Secondary Primary Cancers
National Hospital Organization Kyushu Cancer Center
2016-2025
National Cancer Center Hospital East
2012-2023
Inform (Germany)
2018
Ethica (Canada)
2018
Fukuoka University
2016
Kyushu University
1991-2016
University of Miyazaki Hospital
2016
Shizuoka Cancer Center
2009-2013
Chiba Cancer Center
2012-2013
Osaka Medical Center for Cancer and Cardiovascular Diseases
2012-2013
This phase III study compared treatment with weekly paclitaxel and biweekly irinotecan in patients advanced gastric cancer refractory to fluoropyrimidine plus platinum.Patients were randomly assigned receive either (80 mg/m(2) on days 1, 8, 15, every 4 weeks) or (150 1 weeks). Primary end point was overall survival (OS), secondary points progression-free (PFS), response rate, adverse events, proportion of who received third-line chemotherapy.Of 223 patients, 219 eligible for analysis. Median...
Abstract The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment patients with cancer in clinical trials has not been established. We conducted a phase 2 trial evaluate the efficacy pertuzumab plus trastuzumab for metastatic colorectal (mCRC), human epidermal growth factor receptor ( HER2 ) amplification prospectively confirmed by tissue or ctDNA analysis UMIN000027887 ). was and/or 30 mCRC. study met primary endpoint objective response rate 30% 27 tissue-positive...
G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy KRAS inhibitors has yielded only modest efficacy. Combining the inhibitor sotorasib panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be effective strategy.
This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer.Patients with HER2-positive G/GEJ cancer refractory to first-line chemotherapy combination fluoropyrimidine and platinum were eligible. Patients randomly assigned paclitaxel (80 mg/m2, days 1, 8, 15, every 4 weeks) (PT; initially 8 mg/kg followed by 6 mg/kg, 3 arms. The primary endpoint was...
Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for treatment patients with advanced/metastatic solid tumors ±the anti-programmed cell death-1 antibody, spartalizumab.
This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which these two drugs should be used as initial treatment.The data mCRC were treated or TFTD those drug-naive patients, between June 2014 September 2015, retrospectively collected from 24 institutions Japan. Overall survival (OS) was evaluated using...
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including large-cell inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm, open-label phase 1b study (PROFILE 1013; NCT01121588), malignancies than NSCLC were to receive a starting dose crizotinib 250...
Low concordance between plasma-based and tissue-based tests for determining the RAS mutational status have been reported in some but not all patients with limited-extent metastatic colorectal cancer (mCRC). In this study, we investigated relationship site circulating tumor DNA (ctDNA) detection using ctDNA genotyping, an alternative to tissue genotyping precision oncology.We Guardant360, a next-generation sequencing assay, mCRC single-organ metastasis SCRUM-Japan GOZILA study...
Irinotecan-induced severe neutropenia is associated with homozygosity for the UGT1A1*28 or UGT1A1*6 alleles. In this study, we determined maximum-tolerated dose (MTD) of irinotecan in patients UGT1A1 polymorphisms. Patients who had received chemotherapy other than metastatic gastrointestinal cancer were enrolled. divided into three groups according to genotypes: wild-type (*1/*1); heterozygous (*28/*1, *6/*1); homozygous (*28/*28, *6/*6, *28/*6). Irinotecan was given every 2 weeks two...
3012 Background: LAG525 and spartalizumab (PDR001), humanized IgG4 mAbs, block binding of LAG-3 to MHC class II PD-1 PD-L1 PD-L2, respectively. Preclinical studies show synergistic anti-tumor activity when blocking LAG-3. Here, we report dose escalation results from a Phase I/II study ± in advanced malignancies (NCT02460224). Methods: was dosed Q2W (1–15 mg/kg, or 240/400 mg) Q4W (3–10 400 mg); + at 15 levels/schedules 0.3 mg/kg 1 1000 mg Q4W. I endpoints (dose-limiting toxicities [DLTs],...
Nivolumab, an anti-programmed death-1 agent, showed survival benefits in Asian patients, including Japanese, with gastric/gastro-esophageal junction (G/GEJ) cancer. We report the analysis of Japanese subpopulation from ATTRACTION-2 that evaluated nivolumab versus placebo unresectable advanced or recurrent G/GEJ cancer after ≥ 2 chemotherapy regimens. Data randomized, double-blind, placebo-controlled, phase 3 trial were analyzed (data cutoff, February 25, 2017). Primary endpoint was overall...
Abstract Background Anti-PD-1 monoclonal antibody, nivolumab, has shown efficacy for advanced gastric cancer (AGC). However, the specific immune cell subsets predominantly activated during period of anti-PD-1 therapy AGC have not been clarified. Methods Peripheral blood 30 patients treated with nivolumab was prospectively obtained before initial and second administrations at time progressive disease (PD). The proportions serum concentrations cytokines were systematically analysed by flow...
AimThe KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy as first-line treatment Japanese patients advanced gastric/gastroesophageal junction (G/GEJ) cancer. In this paper, we report results from cohort 1 (S-1 plus oxaliplatin [SOX] pembrolizumab).MethodsThis was a non-randomised, multicentre, open-label phase IIb programmed death-ligand (PD-L1)-positive, human epidermal growth factor receptor 2-negative G/GEJ tumours. The primary endpoint...